The International Commission on the Clinical Use of Human Germline Genome Editing is holding its first public meeting on 13 August in Washington, D.C. The commission has been tasked with developing a framework for scientists, clinicians, and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing. The framework will identify a number of scientific, medical, and ethical requirements that should be considered, and could inform the development of a potential pathway from research to clinical use — if society concludes that heritable human genome editing applications are acceptable.
At the meeting, the commission will hear from invited experts on the current state of understanding on genetics and genetic manipulation and gather perspectives from regulators and industry representatives on translational pathways for somatic (nonheritable) genome editing from the laboratory to treatment. In addition, the commission will be updated on the work of the World Health Organization’s Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing.
The U.S. National Academy of Medicine, the U.S. National Academy of Sciences, and the Royal Society of the United Kingdom are serving as secretariats of the commission, and an international oversight board is overseeing the commission’s work.
Tuesday, 13 August, 2019
8:30 a.m. – 5:15 p.m. EDT
National Academy of Sciences building
2101 Constitution Ave., N.W., Washington, D.C.
Agenda (PDF) | Webcast
Seating is limited. Reporters who wish to attend the meeting should register in advance: